Abstract
Montelukast, a leukotriene receptor antagonist, is the most prescribed nonsteroidal anti-inflammatory drug used as an add-on therapy for asthma. Besides its effect on blocking leukotriene action, montelukast has been proposed to have secondary anti-inflammatory properties. This study aimed to investigate the modulatory effect of montelukast on the expression of major genes involved in airway inflammation (TNF, IL6) and remodeling (MMP9, TGFB1) in response to lipopolysaccharide (LPS) in vitro. The expression of selected genes was measured by quantitative real-time polymerase chain reaction 0h and 24h after LPS stimulation in cells pretreated with montelukast. Montelukast was found to significantly attenuate increased TNF and IL6 gene expression, to have a mild effect on MMP9 and have no effect on TGFB1 expression upon stimulation with LPS. The results of our study indicate that patients on montelukast therapy would have an adequate response to acute microorganism-induced inflammation, so additional anti-inflammatory effects of montelukast should be better exploited.
Funder
Ministry of Education, Science and Technological Development of the Republic of Serbia
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Subject
General Earth and Planetary Sciences,General Environmental Science
Reference34 articles.
1. BERRY, M., BRIGHTLING, C., PAVORD, I., WARDLAW, A. (2007): TNF-alpha in asthma. Current Opinion in Pharmacology 7 (3): 279-282. doi: 10.1016/j.coph.2007.03.001;
2. BISGAARD, H. (2000): Role of leukotrienes in asthma pathophysiology. Pediatric Pulmonology 30: 166-176. doi: 10.1002/1099-0496(200008)30:2<166::AID-PPUL15> 3.0.CO;2-L;
3. CAO, Y., WANG, J., BUNJHOO, H., XIE, M., XU, Y., FANG, H. (2012): Comparison of leukotriene receptor antagonists in addition to inhaled corticosteroid and inhaled corticosteroid alone in the treatment of adolescents and adults with bronchial asthma: a meta-analysis. Asian Pacific Journal of Allergy and Immunology 30: 130-138. Available at: http://apjai-journal.org/wpcontent/uploads/2017/12/6ComparisonVol30No2June2012P130.pdf;
4. DRAGICEVIC, S., MILOSEVIC, K., NESTOROVIC, B., NIKOLIC, A. (2017): Influence of the polymorphism C-509T in the TGFB1 gene promoter on the response to montelukast. Pediatric Allergy, Immunology, and Pulmonology 30: 239-245. doi: 10.1089/ped.2017.0770;
5. DUVERNELLE, C., FREUND, V., FROSSARD, N. (2003): Transforming growth factor-beta and its role in asthma. Pulmonary Pharmacology & Therapeutics 16 (4): 181-196. doi: 10.1016/S1094-5539(03)00051-8;